The IL-23 inhibitor, entering an increasingly competitive space, posted significant results at Digestive Disease Week from the Phase IIb/III QUASAR induction study in ulcerative colitis.
The Janssen Pharmaceutical Cos. of Johnson & Johnson reported positive results from the first of its pivotal trials for Tremfya (guselkumab) in inflammatory bowel disease (IBD) at Digestive Disease Week (DDW) on 9 May, setting the interleukin-23 inhibitor on pace to compete with the two frontrunners in the drug class in the treatment of ulcerative colitis (UC).
Eli Lilly and Company was set to have the first IL-23 inhibitor approved to treat UC, but the US...
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
Coartem Baby to be rolled out in eight African countries in the autumn.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
